Effect of Azathioprine on Skin and Lung Parameters in Patients with Systemic Sclerosis: A Systematic Literature Review
Main Article Content
Abstract
Introduction: Immunosuppressives can be effective in skin and lung involvement in systemic sclerosis(SSc). This study aims to analyse the efficacy of azathioprine in skin and lung parameters in SSc patients, comparing its efficacy with other immunosuppressives.
Method: A systematic literature review was performed. “Patient, intervention, comparison, outcome” method was used to screen studies. All studies that reported pretreatment and posttreatment modified Rodnan skin score (mRSS), forced vital capacity (FVC) and diffusşon capacity for carbon monoxide (DLCO) in SSc patients were included. Meta-analysis was performed where “mean difference” was used to assess the size of the change of pretreatment and posttreatment mean mRSS, FVC and DLCO values in azathioprine group and comparison group.
Results: Ten studies were included. One study demonstrated the role of azathioprine in maintaining the improvement in mRSS after induction treatment with cyclophosphamide. Five studies demonstrated the role of azathioprine as a maintenance agent in SSc interstitial lung disease after cyclophosphamide and three retrospective studies demonstrated the role of azathioprine alone in preserving FVC and DLCO. Two studies were included in meta-analysis of azathioprine and cyclophosphamide, which did not demonstrate significant differences between two drugs in terms of the change in mRSS, FVC and DLCO.
Conclusion: Azathioprine seems to have a role in stabilizing lung function tests after induction treatment with cyclophosphamide. Azathioprine alone can be effective in preserving lung functions a subset of SSc patients with interstitial lung disease. There is no evidence to use azathioprine alone in treatment of skin disease. The failure of meta-analysis to find significant difference between azathioprine and cyclophosphamide is probably due to the major differences in the characteristics of the study populations.
Key points: -There is no evidence that supports use of azathioprine as a monotherapy for skin involvement in systemic sclerosis. Although azathioprine alone may be beneficial in some systemic sclerosis patients with interstitial lung disease, most of the evidence supports its use as a maintenance agent after induction therapy with cyclophosphamide.
-Meta-analyses failed to demonstrate signficant difference between azathioprine and cyclophosphamide, but this is most likely due to the different characteristics of the patient populations in the included studies.
-This is the most extensive systematic literature review that was performed on the effects of azathioprine in skin and lung involvements of systemic sclerosis in the last two decades, which brings together all the recent available data on this drug.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Aringer M, Riemekasten G. Relevance of immunomodulatory therapy for interstitial lung disease in systemic sclerosis. Best Pract Res Clin Rheumatol. 2021 Sep;35(3):101672. doi: 10.1016/j. berh.2021.101672.
3. Götestam Skorpen C, Hoeltzenbein M, Tincani A et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016 May;75(5):795-810. doi: 10.1136/annrheumdi s-2015-208840.
4. Volkmann ER, Andréasson K, Smith V. Systemic sclerosis. Lancet. 2023 Jan 28;401(10373) :304-318. doi: 10.1016/S0140-6736(22)01692-0.
5. Pope JE, Denton CP, Johnson SR, Fernandez-Codina A, Hudson M, Nevskaya T. State-of-the-art evidence in the treatment of systemic sclerosis. Nat Rev Rheumatol. 2023 Apr; 19(4):212-226. doi: 10.1038/s41584-023-00909-5.
6. Tashkin DP, Elashoff R, Clements PJ et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006 Jun 22;354 (25):2655-66. doi: 10.1056/NEJMoa055120.
7. Tashkin DP, Roth MD, Clements PJ et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016 Sep;4(9):708-719. doi: 10.1016/S2213-2600(16)30152-7.
8. Barnes H, Ghazipura M, Herman D et al. Cyclophosphamide in Patients with Systemic Sclerosis-associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis. Ann Am Thorac Soc. 2024 Jan;21(1):122-135. doi: 10.1513/ AnnalsATS.202301-053OC.
9. Herman D, Ghazipura M, Barnes H et al. Mycophenolate in Patients with Systemic Sclerosis-associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis. Ann Am Thorac Soc. 2024 Jan;21(1):136-150. doi: 10.1513/AnnalsATS. 202301-054OC.
10. Hutton B, Salanti G, Caldwell DM et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations. Ann Intern Med. 2015, 162:777-784. 10.7326/M14-2385
11. Higgins JPT, Savović J, Page MJ, Elbers RG, Sterne JAC. Chapter 8: Assessing risk of bias in a randomized trial [last updated October 2019]. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024.
12. Wells GA, Shea B, O'Connell D et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. Ottawa Hospital Research Institute. Published May 3, 2021. Accessed: July 2024. https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp .
13. Schumemann H, Brożek J, Guyatt G, Oxman A. GRADE Handbook. Grading of Recommendations Assessment, Development and Evaluation, Grade Working Group, 2013.
14. Bérezné A, Ranque B, Valeyre D et al. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study. J Rheumatol. 2008, 35(6):1064-72.
15. Dheda K, Lalloo UG, Cassim B, Mody GM. Experience with azathioprine in systemic sclerosis associated with interstitial lung disease. Clin Rheumatol. 2004 Aug;23(4):306-9. doi: 10.1007/s 10067-004-0906-7.
16. Hoyles RK, Ellis RW, Wellsbury J et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 2006;54:3 962-70. 10.1002/art.22204
17. Iudici M, Cuomo G, Vettori S, et al. Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (SSc-ILD): efficacy of maintenance immunosuppression in responders and non-responders. Semin Arthritis Rheum. 2015;44(4):437-44. 10.1016/j.semarthrit. 2014.09.003
18. Kiboshi T, Kotani T, Konma J, et al. Comparison of therapeutic effects of combination therapy with prednisolone and tacrolimus or azathioprine on progressive interstitial pneumonia with systemic sclerosis. Mod Rheumatol. 2022 Feb 28;32(2):358-364. doi: 10.1080/14397595.2021.1918864.
19. Kundu S, Paul S, Hariprasath K, Agarwal R, Ghosh S, Biswas D. Effect of Sequential Intravenous Pulse Cyclophosphamide-Azathioprine in Systemic Sclerosis-Interstitial Lung Disease: An Open-Label Study. Indian J Chest Dis Allied Sci. 2016 Jan-Mar;58(1):7-10.
20. Nadashkevich O, Davis P, Fritzler M, Kovalenko W. A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheumatol. 2006 Mar;25(2):205-12. doi: 10.1007/s10067-005-1157-y
21. Owen C, Ngian GS, Elford K, et al. Mycophenolate mofetil is an effective and safe option for the management of systemic sclerosis-associated interstitial lung disease: results from the Australian Scleroderma Cohort Study. Clin Exp Rheumatol. 2016 Sep-Oct;34 Suppl 100(5):170-176.
22. Paone C, Chiarolanza I, Cuomo G, et al. Twelve-month azathioprine as maintenance therapy in early diffuse systemic sclerosis patients treated for 1-year with low dose cyclophosphamide pulse therapy. Clin Exp Rheumatol. 2007 Jul-Aug;25(4):613-6.
23. Poormoghim H, Rezaei N, Sheidaie Z, et al. Systemic sclerosis: comparison of efficacy of oral cyclophosphamide and azathioprine on skin score and pulmonary involvement-a retrospective study. Rheumatol Int. 2014 Dec;34(12):1691-9. doi: 10.10 07/s00296-014-3026-y.
24. Omair MA, Alahmadi A, Johnson SR. Safety and effectiveness of mycophenolate in systemic sclerosis. A systematic review. PLoS One. 2015 May 1;10 (5):e0124205. doi: 10.1371/journal.pone.0124205.
25. Goswami RP, Ray A, Chatterjee M, Mukherjee A, Sircar G, Ghosh P. Rituximab in the treatment of systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis. Rheumatology (Oxford). 2021 Feb 1;60(2):557-567. doi: 10.1093/ rheumatology/keaa550
26. Khanna D, Lin CJF, Furst DE et al. Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial. Am J Respir Crit Care Med. 2022 Mar 15;205 (6):674-684. doi: 10.1164/rccm.202103-0714OC.
27. Yamasaki Y, Kuwana M. Nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease. Expert Rev Clin Immunol. 2020 Jun;16(6):547-560. doi: 10.1080/1744666X. 2020.1777857.